



drag
1646

PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/032,106
		Filing Date	December 21, 2001
		First Named Inventor	Zaoyuan PENG
		Art Unit	1646
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	8 + 14 Refs.	Attorney Docket Number	433112000700

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 (2 pages in duplicate) 2. References (14) 3. Return receipt postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Shantanu Basu - 43,318
Signature	<i>Shantanu Basu</i>
Date	December 23, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: December 23, 2003	Signature: <i>Martina Placid</i> (Martina Placid)



PATENT
Docket No. 433112000700

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 23, 2003.


Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Zaoyuan PENG et al

Serial No.: 10/032,106

Filing Date: December 21, 2001

For: METHODS FOR IDENTIFYING G-
PROTEIN COUPLED RECEPTORS
ASSOCIATED WITH DISEASES

Examiner: Not Yet Assigned

Group Art Unit: 1646

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:


Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 433112000700. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 23, 2003

Respectfully submitted,

By: 
Shantanu Basu
Registration No. 43,318

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5995
Facsimile: (650) 494-0792

The documents listed on the attached Form PTO-1449 were cited in an Invitation to Pay Fees mailed on August 20, 2003, (copies attached) directed to a counterpart international or foreign application, and were not previously submitted.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search

Form PTO-1449

Docket Number 433112000700

Application Number 10/032,106

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)


Applicant

Zaoyuan PENG et al.

Filing Date December 21, 2001

Group Art Unit 1646

Mailing Date December 23, 2003



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	04/20/2000	WO 00/21985	WIPO			
	2.	06/02/2000	WO 00/31258	WIPO			
	3.	11/02/2000	WO 00/64941	WIPO			
	4.	08/16/2001	WO 01/59113	WIPO			
	5.	09/20/2001	WO 01/68805	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	6.	Database Accession no. AC025497. Last updated on July 13, 2000, (July 2000). located at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=9857601&opt=(... Last Visited on September 9, 2003. Total pages 23.
	7.	Database Accession no. AP001112. Last updated on July 13, 2000, (August 2000). located at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=9857601&opt=(... Last Visited on September 9, 2003. Total pages 35.
	8.	Database Accession no. AX214095. Last updated on September 06, 2001, (September 2001). located at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=9857601&opt=(... Last Visited on September 9, 2003. Total pages 1.
	9.	Invitation To Pay Fee mailed on August 20, 2003, for PCT patent application no. PCT/US01/50242 filed on December 21, 2001, 9 pages.
	10.	International Search Report mailed on November 13, 2003, for PCT patent application no. PCT/US01/50242 filed on December 21, 2001, 13 pages.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 433112000700

Application Number 10/032,106

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Zaoyuan PENG et al.

Filing Date December 21, 2001

Group Art Unit 1646

Mailing Date December 23, 2003

- | | |
|-----|---|
| 11. | Lohse, M. J. et al. (1996). "Mechanisms of Beta-Adrenergic Receptor Desensitization: From Molecular Biology to Heart Failure," <i>Basic Research in Cardiology</i> 91 (Suppl. 2):29-34. |
| 12. | Mirmics, X. et al. (2001). "Disease-Specific Changes in Regulator of G-Protein Signaling 4 (RGS4) Expression in Schizophrenia," <i>Molecular Psychiatry</i> 6(3):293-301. |
| 13. | Stadel, J. M. et al. (1997). "Orphan G Protein-Coupled Receptors: A Neglected Opportunity for Pioneer Drug Discovery," <i>Trends in Pharmacological Sciences</i> 18(11):430-437. |
| 14. | Winkles, J. A. et al. (1993). "Endothelin-1 and Endothelin Receptor mRNA Expression in Normal and Atherosclerotic Human Arteries," <i>Biochemical and Biophysical Research Communications</i> 191(3):1081-1088. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

